Mumbai Records 25% Surge in Minimally Invasive Heart Procedures
Mumbai has recorded a 25% year-on-year increase in Transcatheter Aortic Valve Replacement (TAVR) procedures, signaling a major shift toward minimally invasive cardiac therapies in the city. This growth reinforces Mumbai's position as India's most mature cardiac care ecosystem, attracting patients from across the country and international markets.
TAVR is increasingly becoming the preferred treatment for severe aortic stenosis, a common heart valve disorder in individuals aged 60 and above. The condition occurs when the aortic valve narrows, restricting blood flow from the heart. Symptoms such as breathlessness, fatigue, chest discomfort, and dizziness are often mistaken for normal ageing, leading to delayed diagnosis and treatment. Untreated severe aortic stenosis can result in heart failure, reduced quality of life, and increased mortality risk.
Drivers of Growth in TAVR Adoption
The rise in TAVR procedures is attributed to greater awareness of structural heart disease, earlier diagnosis, and expanding eligibility to intermediate- and lower-risk patients, including appropriately selected younger individuals. Advanced imaging, hybrid catheterization labs, and multidisciplinary Heart Teams are enabling more personalized treatment planning and management of complex cases.
"Over the past few years, Mumbai has witnessed a steady increase in the adoption of minimally invasive cardiac therapies, particularly TAVR. Advances in technology, imaging and procedural planning have significantly improved outcomes while enabling patients to recover faster and return to their daily lives sooner," said Dr. Haresh Mehta, Director of Interventional & Structural Cardiology at S. L. Raheja Hospital, Mumbai.
Clinical Evidence Supports Minimally Invasive Approach
A landmark seven-year study published in The New England Journal of Medicine involving nearly 1,000 patients found no significant differences between TAVR and surgery in rates of death (19.5% vs. 16.8%), stroke (8.5% vs. 8.1%), and rehospitalization (20.6% vs. 23.5%). Patients undergoing TAVR typically recover within two to three days and return to daily activities sooner than those who undergo conventional surgery.
"Today's focus extends beyond the procedure itself. We are increasingly looking at lifetime management, valve durability and future treatment pathways when needed. TAVR has transformed the treatment landscape for aortic stenosis by offering patients a less invasive option without compromising outcomes. With continued advancements in technology and growing clinical experience, India is now delivering structural heart care comparable to leading centres globally," added Dr. Mehta.
Mumbai's Integrated Cardiac Ecosystem
Mumbai's integrated, technology-driven cardiac ecosystem is a key factor in its leadership. The city's hospitals are equipped with advanced imaging and hybrid cath labs, supported by specialized Heart Teams that coordinate care from diagnosis to follow-up. This infrastructure enables the management of increasingly complex structural heart cases with greater precision.
As life expectancy following valve interventions increases, clinicians are focusing on lifetime management strategies. The demand for TAVR is expected to continue growing as awareness spreads and access to advanced interventions expands. Mumbai is well positioned to lead the next phase of cardiac care innovation in India, offering outcomes comparable to leading global centers.
